Fecal Calprotectin concentration in children affected by SIBO

European Review for Medical and Pharmacological Sciences

Volumn 15, Issue 11, 2011, Pages 1328-1335

  Fundaro C ^a   Fantacci, C ^a   Ansuini, V ^a   Giorgio, V ^a   Filoni, S ^a   Barbaro, F ^a   Gasbarrini, A ^a   Rossi, C ^a  

^a FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

Author keywords

Children; Fecal calprotectin; Lactulose breath test; Small intestinal bacterial overgrowth

Indexed keywords

CALGRANULIN; LACTULOSE;

ADOLESCENT; BACTERIAL OVERGROWTH; BODY WEIGHT; BREATH ANALYSIS; CHILD; CONTROLLED STUDY; FECES ANALYSIS; FEMALE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PROSPECTIVE STUDY; PROTEIN EXPRESSION; REVIEW; SCHOOL CHILD; SMALL INTESTINE BACTERIAL OVERGROWTH; ARTICLE; CHEMISTRY; ENTEROPATHY; FECES; INFECTION; MICROBIOLOGY; PATHOLOGY; SMALL INTESTINE;

BREATH TESTS; CHILD; FECES; FEMALE; HUMANS; INFECTION; INFLAMMATION; INTESTINAL DISEASES; INTESTINE, SMALL; LACTULOSE; LEUKOCYTE L1 ANTIGEN COMPLEX; MALE; PROSPECTIVE STUDIES;

EID: 84855990431     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (49)

1. FAGERHOL MK. Nomenclature for proteins: is Calprotectin a proper name for the elusive myelomonocytic protein? J Clin Pathol 1996; 49: M74-79. (Pubitemid 26143349)
2. DORIN JR, EMSLIE E, VAN HEYNINGEN V. Related calcium- bindings proteins map to the same subregion of chromosome 1q and to an extended region of synteny on mouse chromosome 3. Genomics 1990; 8: 420-426.
3. SCHÄFER BW, HEIZMANN CW. The S100 family of EFhand calcium-binding proteins: functions and pathology. Trends Biochem Sci 1996; 21: 134-140. 1333 Fecal Calprotectin concentration in children affected by SIBO
4. FAGERHOL MK, DALE I, ANDERSON I. Release and quantitation of a leukocyte derived protein (L1). Scand J Haematol 1980; 24: 393-398. (Pubitemid 10080486)
5. JOHNE B, FAGERHOL MK, LYBERG T, PRYDZ H, BRANDTZAEG P, NAESS-ANDRESEN CF, DALE I. Functional and clinical aspects of the myelomonocyte protein calprotectin. Mol Pathol 1997; 50: 113-123. (Pubitemid 27454995)
6. BERNTZEN HB, FAGERHOL MK. LI, a major granulocyte protein: isolation of high quantities of its subunits. Scand J Clin Lab Invest 1990; 50: 769-774. (Pubitemid 20369265)
7. VOGANATSI A, PANYUTICH A, MIYASAKI KT, MURTHY RK. Mechanism of extracellular release of human neutrophil calprotectin complex. J Leukoc Biol 2001; 70: 130-134. (Pubitemid 32613672)
8. POULLIS A, FOSTER R, MENDALL MA, FAGERHOL MK. Emerging role of calprotectin in gastroenterology. J Gastr Hepatol 2003; 18: 756-762. (Pubitemid 36936565)
9. BERNI CANANI R, ROMANO MT, TERRIN G, RAPACCIUOLO L. Fecal calprotectin is a useful diagnostic tool in pediatric gastroenterology. It J Pediatr 2005; 32: 89-94. (Pubitemid 41134028)
10. NAESS-ANDRESEN CF, ENGELANDSDAL B, FAGERHOL MK. Calcium binding and concomitant changes in the structure and heat stability of calprotectin (L1 protein). Clin Mol Pathol 1995; 48: M278-284.
11. RøSETH AG. Determination of fecal calprotectin, a novel marker of organic gastrointestinal disorders. Dig Liver Dis 2003; 35: 607-609. (Pubitemid 41110869)
12. AADLAND E, FAGERHOL MK. Fecal calprotectin: a marker of inflammation throughout the intestinal tract. Eur J Gastroenterol Hepatol 2002; 14: 823-825. (Pubitemid 34913578)
13. RøSETH AG, FAGERHOL MK, AADLAND E, SCHJøNSBY H. Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study. Scand J Gastroenterol 1992; 27: 793-798.
14. OLAFSDOTTIR E, AKSNES L, FLUGE G, BERSTAD A. Faecal calprotectin levels in infants with infantile colic, healthy infants, children with inflammatory bowel disease, children with recurrent abdominal pain and healthy children. Acta Paediatr 2002; 91: 45-50. (Pubitemid 34151218)
15. KAISER T, LANGHORST J, WITTKOWSKI H, BECKER K, FRIEDRICH AW, RUEFFER A, DOBOS GJ, ROTH J, FOELL D. Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome. Gut 2007; 56: 1706-1713. (Pubitemid 350206297)
16. BERNI CANANI R, RAPACCIUOLO L, ROMANO MT, TANTURRI DE HORATIO L, TERRIN G, MANGUSO F, CIRILLO P, PAPARO F, TRONCONE R. Diagnostic value of faecal calprotectin in pediatric gastroenterology clinical practice. Dig Liver Dis 2004; 36: 467-470. (Pubitemid 41115450)
17. CARROCCIO A, IACONO G, COTTONE M, DI PRIMA L, CARTABELLOTTA F, CAVATAIO F, SCALICI C, MONTALTO G, DI FEDE G, RINI G, NOTARBARTOLO A, AVERNA MR. Di agnostic accuracy of fecal calprotectin assay in distinguishing organic causes of chronic diarrhea from irritable bowel syndrome: a prospective study in adults and children. Clin Chem 2003; 49: 861-867. (Pubitemid 36623463)
18. BAYELI PF, MARIOTTINI M, LISI L, FERRARI P, TEDONE F. Guidelines on intestinal dysmicrobism (SIBO Small Intestine Bacterial Overgrowth). Minerva Gastroenterol Dietol 1999; 45: 297-308. (Pubitemid 30084202)
19. RANA SV, BHARDWAJ SB. Small intestinal bacterial overgrowth. Scand J Gastroenterol 2008; 43: 1030-1037.
20. SINGH VV, TOSKES PP. Small bowel bacterial overgrowth: presentation, diagnosis, and treatment. Curr Treat Options Gastroenterol 2004; 7: 19-28. (Pubitemid 38923716)
21. RHODES JM, MIDDLETON P, JEWELL DP. The lactulose hydrogen breath test as a diagnostic test for small-bowel bacterial overgrowth. Scand J Gastroenterol 1979; 14: 333-336. (Pubitemid 9185710)
22. MENDOZA E, CRISMATT C, MATOS R, SABAGH O, CAMPO M, CEPEDA J, VILLANUEVA D. Diagnosis of small intestinal bacterial overgrowth in children: the use of lactulose in the breath hydrogen test as a screening test. Biomedica 2007; 27: 325-332. (Pubitemid 351890520)
23. VON ROON AC, KARAMOUNTZOS L, PURKAYASTHA S, REESE GE, DARZI AW, TEARE JP, TEARE JP, PARASKEVA P, TEKKIS PP. Diagnostic precision of fecal calprotectin for inflammatory bowel diseases and colorectal malignancy. Am J Gastroenterol 2007; 102: 803-813. (Pubitemid 46496634)
24. MONTALTO M, SANTORO L, DALVAI S, CURIGLIANO V, D'ONOFRIO F, SCARPELLINI E, CAMMAROTA G, PANUNZI S, GALLO A, GASBARRINI A, GASBARRINI G. Fecal calprotectin concentrations in patients with small intestinal bacterial overgrowth. Dig Dis 2008; 26: 183-186. (Pubitemid 351572144)
25. BUNN SK, BISSET WM, MAIN MJC, GRAY ES, OLSON S, GOLDEN BE. Fecal Calprotectin: validation as a noninvasive measure of bowel inflammation in childhood inflammatory bowel disease. J Pediatr Gastr Nutr 2001; 33: 14-22. (Pubitemid 32706118)
26. LEACH ST, YANG Z, MESSINA I, SONG C, GECZY CL, CUNNINGHAM AM, DAY AS. Serum and mucosal S100 proteins, calprotectin (S100A8/S100A9) and S100A12, are elevated at diagnosis in children with inflammatory bowel disease. Scand J Gastroenterol 2007; 42: 1321-1331. (Pubitemid 47537067)
27. DE JONG NS, LEACH ST, DAY AS. Fecal S100A12: a novel noninvasive marker in children with Crohn's disease. Inflamm Bowel Dis 2006; 12: 566-572. (Pubitemid 43977737)
28. FAGERBERG UL, LÖÖF L, MYRDAL U, HANSSON LO, FINKEL Y. Colorectal inflammation is well predicted by fecal calprotectin in children with gastrointestinal symptoms. J Pediatr Gastr Nutr 2005; 40: 450-455. (Pubitemid 40489572)
29. RøSETH AG, SCHMIDT PN, FAGERHOL MK. Correlation between faecal excretion of Indium-111-labelled granulocytes and Calprotectin, a granulocyte marker protein, in patients with inflammatory bowel disease. Scand J Gastroenterol 1999; 34: 50-54. (Pubitemid 29074787)
30. LIMBURG PJ, AHLQUIST DA, SANDBORN WJ, MAHONEY DW, DEVENS ME, HARRINGTON JJ, ZINSMEISTER AR. Fecal Calprotectin levels predict colorectal inflammation among patients with chronic diarrhea referred for colonscopy. Am J Gastroenterol 2000; 95: 2831-2837.
31. RøSETH AG, AADLAND E, GRZYB K. Normalization of Fecal Calprotectin: a predictor of mucosal healing in patients with inflammatory bowel diseases. Scand J Gastroenterol 2004; 39: 1017-1020. (Pubitemid 39388470)
32. RøSETH AG, AADLAND E, JAHNSEN J, RAKNERUD N. Assessment of disease activity in ulcerative colitis by faecal calprotectin, a novel granulocyte marker protein. Digestion 1997; 58: 176-180. (Pubitemid 27163169)
33. HO GT, LEE HM, BRYDON G, TING T, HARE N, DRUMMOND H, SHAND AG, BARTOLO DC, WILSON RG, DUNLOP MG, ARNOTT ID, SATSANGI J. Fecal calprotectin predicts the clinical course of acute severe ulcerative colitis. Am J Gastroenterol 2009; 104: 673-678.
34. DIAMANTI A, COLISTRO F, BASSO MS, PAPADATOU B, FRANCALANCI P, BRACCI F, MURACA M, KNAFELZ D, DE ANGELIS P, CASTRO M. Clinical role of calprotectin assay in determining histological relapses in children affected by inflammatory bowel diseases. Inflamm Bowel Dis 2008; 14: 1229-1235.
35. TIBBLE JA, SIGTHORSSON G, BRIDGER S, FAGERHOL MK, BJARNASON I. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology 2000; 119: 15-22. (Pubitemid 30452574)
36. PARDI DS, SANDBORN WJ. Predicting relapse in patients with inflammatory bowel disease: what is the role of biomarkers? Gut 2005; 54: 321-322. (Pubitemid 40299082)
37. SAPS M, DI LORENZO C. Diagnosis and managing functional symptoms in the child with inflammatory bowel disease. J Pediatr Gastr Nutr 2004; 39: S760-762.
38. BJARNASON I, SHERWOOD R. Fecal Calprotectin: a significant step in the noninvasive assessment of intestinal inflammation. J Pediatr Gastr Nutr 2001; 33: 11-13. (Pubitemid 32706117)
39. SCARPELLINI E, GABRIELLI M, LAURITANO CE, LUPASCU A, MERRA G, CAMMAROTA G. High dosage rifaximin for the treatment of small intestinal bacterial overgrowth. Aliment Pharm Ther 2007; 25: 781-786. (Pubitemid 46434913)
40. GREGG CR. Enteric bacterial flora and bacterial overgrowth syndrome. Semin Gastrointest Dis 2002; 13: 200-209. (Pubitemid 35351252)
41. JONES MP, BRATTEN JR. Small intestinal motility. Curr Opin Gastroenterol 2008; 24: 164-172. (Pubitemid 351322782)
42. SHI HN, WALKER A. Bacterial colonization and the development of intestinal defences. Can J Gastroenterol 2004; 18: 493-500. (Pubitemid 39248249)
43. BIANCONE L, MONTELEONE I, DEL VECCHIO BLANCO G, VAVASSORI P, PALLONE F. Resident bacterial flora and immune system. Dig Liver Dis 2002; 34: S37-43.
44. KING CE, TOSKES PP. Small intestinal bacterial overgrowth. Gastroenterology 1979; 76: 1035-1055.
45. GRACEY M, BURKE V, OSHIN A, BARKER J, GLASGOW EF. Bacteria, bile salts and intestinal monosaccharide malabsorption. Gut 1971; 12: 683-692.
46. GIANNELLA RA, ROUT WR, TOSKES PP. Jejunal brush border injury and impaired sugar and amino acid uptake in the blind loop syndrome. Gastroenterology 1974; 67: 965-974.
47. RIORDAN SM, MCIVER CJ, WAKEFIELD D, DUNCOMBE VM, THOMAS MC, BOLIN TD. Small intestinal mucosal immunity and morphometry in luminal overgrowth of indigenous gut flora. Am J Gastroenterol 2001; 96: 494-500.
48. LAPPINGA PJ, ABRAHAM SC, MURRAY JA, VETTER EA, PATEL R, WU TT. Small intestinal bacterial overgrowth: histopathologic features and clinical correlates in an underrecognized entity. Arch Pathol Lab Med 2010; 134: 264-270.
49. KETT K, BAKLIEN K, BAKKEN A, KRAL CJ, FAUSA O, BRANDTZAEQ P. Intestinal B-cell isotype response in relation to local bacterial load. Evidence for immunoglobulin A subclass adaptation. Gastroenterology 1995; 109: 819-825.